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Introduction
Polo-like kinase 1 (Plk1) is a conserved protein kinase control-
ling many of the key events of mitosis and cytokinesis (Barr 
et al., 2004). In prometaphase and metaphase, it is found on 
centrosomes  and  kinetochores  where  it  promotes  formation 
of a bipolar mitotic spindle (Lane and Nigg, 1996; Liu and   
Erikson, 2002; Sumara et al., 2004). Subsequently, it relocates 
to the central spindle in anaphase and activates Rho-GTPase   
regulators, initiating cleavage furrow formation and cell con-
tractility (Golsteyn et al., 1995; Brennan et al., 2007; Burkard 
et al., 2007, 2009; Petronczki et al., 2007; Santamaria et al.,   
2007; Wolfe et al., 2009). A conserved phosphopeptide-binding 
domain, the Polo-box domain, is responsible for this com-
plex pattern of spatial and temporal control (Cheng et al., 
2003; Elia et al., 2003a,b). Through this domain, Polo kinases   
bind to phosphorylated partners containing a conserved motif 
(Elia et al., 2003a). This leads to concentration at particular sites 
and increased levels of kinase activity. According to the prevail-
ing model, Cdk1–cyclin B creates these docking sites in pro-
phase and metaphase (Cheng et al., 2003; Elia et al., 2003a,b), 
whereas in anaphase, self-priming by Plk1 itself predominates 
(Neef et al., 2007; Burkard et al., 2009). In anaphase, Plk1 self-
primes a docking site at the C terminus of the anaphase spindle 
and microtubule-associated protein PRC1 on T602 and is then 
recruited to the central spindle (Neef et al., 2007).
Consistent with these mitosis-specific functions, Plk1 is 
slowly degraded as cells exit mitosis and is essentially absent   
by the time cells undergo cytokinesis (Golsteyn et al., 1994, 1995; 
Lindon and Pines, 2004). The anaphase-promoting complex/
cyclosome–Cdh1 ubiquitin ligase is required for Plk1 degrada-
tion (Lindon and Pines, 2004). Anaphase-promoting complex/
cyclosome–Cdh1 recognizes Plk1 as a target for ubiquitylation 
through a conserved destruction box (D-box) motif and, thus, 
earmarks  it  for  proteasomal  degradation  (Lindon  and  Pines, 
2004). However, although degradation of Plk1 as animal cells 
exit mitosis is clearly important in the control of mitotic exit and   
cytokinesis (Lindon and Pines, 2004), the mechanistic detail of 
its function at this time remains unclear.
Cytokinesis is terminated by a membrane-remodeling and 
fission event termed abscission that is mediated by the ESCRT-III 
membrane–remodeling proteins (Carlton and Martin-Serrano, 
2007), which is an ancestral part of the cytokinesis machinery 
shared with Archaea (Samson et al., 2008). In dividing mam-
malian cells, ESCRT-III is specifically nucleated on the surface 
of the preassembled midbody by the Cep55 adaptor protein. 
C
ytokinesis requires a membrane-remodeling and 
fission event termed abscission that occurs after 
chromosome  segregation,  cleavage  furrow  for-
mation, and contraction have completed. In this study, we 
show how abscission factor recruitment is controlled by 
the Polo-like kinase 1 (Plk1). At the metaphase–anaphase 
transition, Plk1 initiates cleavage furrow formation and 
is then progressively degraded during mitotic exit. During 
this  period,  Plk1  phosphorylates  the  abscission  factor 
Cep55 in trans and prevents its untimely recruitment to 
the anaphase spindle. A Plk1 phosphorylation site mutant 
of Cep55 is prematurely recruited to the anaphase spin-
dle and fails to support abscission. Endogenous Cep55   
behaves similarly after Plk1 inhibition by the drugs BI2536 
or GW842862. Only once Plk1 is degraded can Cep55 
target  to  the  midbody  and  promote  abscission.  Block-
ing Plk1 degradation leads to elevated levels of Plk1 at 
the midbody and the failure of Cep55 recruitment. Thus, 
Plk1 activity negatively regulates Cep55 to ensure orderly 
abscission factor recruitment and ensures that this occurs 
only once cell contraction has completed.
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Figure 1.  Plk1 phosphorylation negatively regulates the interaction of Cep55 with the midbody component MKlp1. (A, top) HeLa cells stably expressing 
EGFP-tagged -tubulin (green) and mCherry-tagged histone H2B (red) were treated with 1 µM BI256. Still images from videos are indicated with arrows to 
mark the position of the midbody and intracellular bridge. Bar, 10 µm. (bottom) The model depicts the decay in Plk1 levels and activity in anaphase while 
chromosome segregation by the microtubule spindle is taking place and the outcomes of inhibiting Plk1 in early or late anaphase. Lines at the second time 
point indicate the extent of chromosome segregation. Dotted lines in the last time point mark the outline of the binucleate cells. (B) HeLa cells in anaphase or 
undergoing cytokinesis were treated with DMSO (control) or 1 µM BI2536 for 25 min. Cep55 and MKlp1 complexes were isolated with sheep antibodies   
and analyzed by quantitative nano liquid chromatography MS/MS. The ratio of identified proteins in BI2536 and control conditions was plotted for 
anaphase versus midbody stages. Green dots indicate midbody proteins, red dots mark proteins increased after Plk1 inhibition in anaphase, and blue 
dots indicate other proteins. (C) The response of midbody proteins to Plk1 inhibition is summarized in the table. The number of peptides found is listed in 753 Plk1 acts as a timer for abscission • Bastos and Barr
the control and BI2536 columns. Fold change in abundance based on the summed intensities of the peptides forming each protein group was calculated 
using MaxQuant. IP, immunoprecipitation. (D) The same samples were Western blotted. (E) Western blotting of MKlp1 and Cep55 complexes isolated from 
synchronized HeLa cells at the different stages of mitosis. Western blot markers are given in kilodaltons.
 
Cep55 directly interacts with the central MKlp1 component of   
the midbody and the ESCRT proteins ALIX and TSG101   
(Fabbro et al., 2005; Martinez-Garay et al., 2006; Zhao et al., 
2006; Carlton and Martin-Serrano, 2007; Morita et al., 2007; 
Carlton et al., 2008; Lee et al., 2008). This series of events, 
whereby abscission components are recruited only after mid-
body formation when the plasma membrane is pulled down to 
a narrow 0.5-µm-diameter tube of membrane connecting the 
two daughter cells, may be caused by the limitations of the 
membrane-remodeling properties of ESCRT-III (Wollert et al.,   
2009). At  earlier  times,  when  the  plasma  membrane  is  less 
closely apposed and has a larger radius of curvature, ESCRT-III 
cannot promote the membrane-remodeling event leading to 
abscission. In addition, other membrane delivery and microtubule-
remodeling events have to occur before abscission can be trig-
gered (Kouranti et al., 2006; Barr and Gruneberg, 2007; Simon 
et al., 2008). Thus, timing is critical for efficient abscission, yet 
it remains unclear how this is achieved.
Results and discussion
Identification of Plk1-sensitive  
midbody components
Previous studies have indicated that Plk1 has unexplained func-
tions in the late stages of cytokinesis (Lindon and Pines, 2004; 
Santamaria et al., 2007). To confirm this idea, the rapid-acting 
Plk1 inhibitor BI2536 was used (Lénárt et al., 2007; Steegmaier 
et al., 2007). When Plk1 was inhibited as chromosome segrega-
tion initiated in early anaphase, cleavage furrow formation failed 
(Fig. 1 A, top). However, although furrow formation was not ob-
viously perturbed when BI2536 was added as chromosomes 
reached the maximum point of segregation later in anaphase, 
cytokinesis ultimately failed and the cells became binucleate 
(Fig. 1 A, bottom). These observations suggest that Plk1 may 
function as the control of abscission.
To identify central spindle and midbody proteins whose 
levels alter according to the activity of Plk1, MKlp1 complexes 
were isolated from early anaphase cells treated with solvent 
control or BI2536 to inhibit Plk1 and then analyzed by mass 
spectrometry (MS). To give a second dimension to the analysis, 
this was repeated for cells at a later stage where midbodies had 
formed. MKlp1 is predominantly in a complex with the Rho 
family GAP Cyk4 and PRC1, and these proteins cluster together 
about the center of the plot (Fig. 1 B). Plk1 inhibition with 
BI2536 shifts Cep55 away from this cluster, corresponding to 
an increase of >37-fold (Fig. 1, B–D), indicating that it is a Plk1-
sensitive component of MKlp1 complexes. Reciprocal isolation   
of Cep55 was performed to corroborate these observations. This 
showed that Cep55 was found predominantly in a complex with   
the ESCRT protein ALIX in control cells (Fig. 1 C). After BI2536 
treatment, >30-fold increases in the amounts of MKlp1 and 
Cyk4 were observed (Fig. 1, B–D). MKlp1 and Cyk4 were   
the only components altered by Plk1 inhibition in this way, 
which  is  consistent  with  these  proteins  forming  a  hetero-
oligomeric  complex  (Mishima  et  al.,  2002).  Other  midbody 
components such as the 14–3-3 proteins (Douglas et al., 2010) 
were not altered by Plk1 inhibition (Fig. 1 B). To investigate 
whether the Cep55–MKlp1 interaction occurs in normal cyto-
kinesis in the absence of Plk1 inhibitors, MKlp1 complexes were 
isolated throughout mitosis and cytokinesis. Cep55 was only 
precipitated together with MKlp1 from anaphase onwards when 
phosphorylation on Cep55 at the conserved Plk1 site at S436 
was lost (Fig. 1 E). Therefore, Plk1 phosphorylation may nega-
tively regulate the interaction of Cep55 with the midbody com-
ponent MKlp1 in anaphase cells and could provide an inhibitory 
signal preventing premature abscission factor recruitment.
Central spindle–targeted Plk1 is a negative 
regulator of Cep55 recruitment
To provide further evidence that Plk1 is a specific regulator 
of  Cep55,  cells  were  treated  with  specific  chemical  inhibi-
tors to Cdk1 (flavopiridol; Potapova et al., 2006), aurora B   
(ZM447439;  Ditchfield  et  al.,  2003),  and  Plk1  (BI2536  or 
GW843682; Lansing et al., 2007; Lénárt et al., 2007). In control 
cells, Cep55 showed the expected pattern of late recruitment to 
the midbody in cytokinesis (Fig. 2 A, Fig. S1 A, and Video 1). 
Strikingly, Plk1 inhibition with BI2536 or GW843682 resulted 
in premature recruitment of Cep55 to the central spindle in ana-
phase and telophase (Fig. 2 A; and Fig. S1, A–C). The Cep55 
partner and ESCRT-III component ALIX was also prematurely 
recruited to the central spindle in a Cep55-dependent manner 
after Plk1 inhibition with BI2536 (Fig. S2, A and B). Premature 
recruitment of Cep55 to the anaphase spindle was not seen with 
Cdk1 and aurora B inhibitors; although after these treatments 
cells showed chromosome segregation errors, they still formed 
Cep55-positive midbodies during cytokinesis (Fig. 2 A; and 
Fig. S1, D and E).
In anaphase, Plk1 self-primes its own binding to the ana-
phase  spindle  microtubule-associated  protein  PRC1  at T602 
(Neef et al., 2007). As predicted by this model, when cells are 
treated with the Plk1 inhibitor BI2536 for 5 min, PRC1 T602 
phosphorylation is lost, and Plk1 is absent from the central spin-
dle in anaphase and telophase (Figs. 2 A and S3). The absence 
of Plk1 correlated with the appearance of Cep55 at the central 
spindle under these conditions (Fig. 2 A). Furthermore, cells 
expressing only a Plk1-binding defective ST602AA mutant of 
PRC1 were unable to recruit Plk1 to the central spindle in anaphase 
yet showed premature recruitment of Cep55 (Fig. 2 B). These 
observations provide further support both for the model that PRC1 
is a major structural partner for Plk1 at the central spindle and 
the role of Plk1 as a negative regulator of Cep55 recruitment.
Plk1 phosphorylates Cep55 on S436 within a C-terminal   
region containing the binding site for MKlp1 (Fabbro et al., 2005; 
Zhao et al., 2006). Cep55 complexes isolated from early ana-
phase cells treated with solvent control, BI2536, or ZM447439 
were therefore Western blotted with Cep55 pS436 antibodies. JCB • VOLUME 191 • NUMBER 4 • 2010   754
as the wild-type protein and targeted to the midbody only late 
in cytokinesis (Fig. 3 A). This is the same behavior seen with 
Cep55 antibodies (Fig. 2 A). In contrast, the S436A mutant was 
present at the central spindle from early anaphase (Fig. 3 A).   
This recapitulates the behavior of wild-type Cep55 when Plk1 
is  inhibited  (Fig.  2 A).  Live  cell  imaging  also  showed  that 
Cep55 S436A was prematurely recruited to the central spindle 
and then accumulated to higher levels than the wild-type pro-
tein at the midbody (Fig. 3 B). Typically, Cep55 was recruited 
60 min after the onset of anaphase, whereas Cep55 S436A was   
visible on the central spindle after 5–10 min (Fig. 3 B, bar graph).   
This revealed that endogenous Cep55 phosphorylation at S436 
is sensitive to Plk1 but not aurora B inhibition and that MKlp1 
is only present when S436 phosphorylation is absent (Fig. 2 C).   
These same lysates were used for the isolation of MKlp1 com-
plexes. This revealed that the Cep55 present in MKlp1 complexes 
was  not  phosphorylated  at  S436  (Fig.  2,  compare  C  and  D).   
To  test  the  functional  consequences  of  this  phosphoryla-
tion by Plk1, the conserved Plk1 sites in Cep55 were mutated, 
and stable doxycycline-inducible cell lines produced express-
ing EGFP-tagged forms of the wild-type and mutant forms of 
Cep55. The N-terminal T46A, S47A double mutant behaved 
Figure 2.  Plk1 phosphorylation negatively regulates central spindle recruitment of Cep55. (A) HeLa cells treated with DMSO, 1 µM BI2536, 5 µM flavo-
piridol, or 1 µM ZM447439 for 25 min were stained for DNA with DAPI and mouse anti–-tubulin, rabbit anti-Cep55 (green), and goat anti-Plk1 (red).   
(B) HeLa cells transiently expressing EGFP-PRC1 or the Plk1-binding defective ST602AA mutant were transfected with control or PRC1 3 untranslated region 
(UTR) siRNAs for 36 h. Cells were stained for DNA with DAPI, sheep anti-Cep55 (false-colored green in the merge), and goat anti-Plk1 (red). PRC1 was 
visualized using EGFP fluorescence. (C and D) Cep55 (C) and MKlp1 (D) complexes were isolated using sheep antibodies from mitotic HeLa cells treated 
with DMSO (control), 1 µM BI2536, or 1 µM ZM447439 for 25 min and then Western blotted. The asterisks indicate cross-reactivity to the heavy chain of 
the antibody used for immunoprecipitation. Western blot markers are given in kilodaltons. Bars, 10 µm.755 Plk1 acts as a timer for abscission • Bastos and Barr
Figure 3.  Cep55 S436A is prematurely recruited to the central spindle in anaphase. (A) HeLa cells transiently expressing EGFP-tagged wild-type, 
TS46, 47AA, and S436A mutant Cep55 were stained for DNA with DAPI and mouse anti–-tubulin. Bar, 10 µm. (B, left) HeLa cells stably expressing 
doxycycline-inducible mCherry-Cep55 or the S436A mutant of Cep55 were imaged as they exited mitosis. Insets in phase-contrast images show enlarge-
ments of the midbody region (arrows). Times are shown in hours and minutes from the onset of anaphase. Bar, 5 µm. (right) The time of Cep55 recruitment 
from the start of anaphase was measured in wild-type and S436A-expressing cells and is plotted as a bar graph (n = 10). Error bars indicate SD. (C) The   
fluorescence intensity of Cep55 was measured for the full 3D central spindle and midbody volume using the quantitation and tracking software and is plot-
ted against time for both wild-type Cep55 and the S436A mutant–expressing cells. Arrows indicate the point of metaphase to anaphase transition obtained 
by inspection of the chromosomes in phase-contrast images. All timings are set relative to this point.JCB • VOLUME 191 • NUMBER 4 • 2010   756
These cells remained arrested at the midbody stage for many   
hours (Fig. 3 B, insets). Measurements of Cep55 levels at the   
central spindle and midbody confirmed that Cep55 S436A re-
cruitment occurs with more rapid kinetics and accumulates to 
higher levels than the wild-type protein (Fig. 3 C). These obser-
vations support the proposal that Plk1 is a negative regulator of 
Cep55 recruitment.
Plk1 degradation is required for Cep55 
recruitment to the midbody
A key aspect of the model proposed in this study is that Plk1 
degradation acts as a timer for Cep55 recruitment. Accordingly, 
preventing  Plk1  degradation  with  the  proteasomal  inhibitor 
MG132 resulted in increased levels of Plk1 at MKlp1 midbody 
structures after 120-min treatment compared with control cells 
(Fig. 4 A). As expected, Cep55 was absent from these Plk1- 
positive midbody structures (Fig. 4 A). To investigate this in 
more detail, inducible stable cells lines expressing EGFP-tagged   
Cep55  and  either  wild-type  or  D-box  mutant  mCherry-tagged 
Plk1 were created. Live cell imaging confirmed that there is an   
inverse correlation between Plk1 and Cep55 levels at the mid-
body  during cytokinesis (Fig. 4, B [left] and D). Furthermore, 
MG132 reduces Plk1 degradation and, thus, prevents recruit-
ment of Cep55 to the midbody. Inhibition of this MG132-
stabilized Plk1 triggers immediate recruitment of Cep55 to the 
midbody (Fig. 4, B [right] and D), supporting the idea that Plk1 
is a key factor stabilized by MG132 addition. Cep55 recruit-
ment to the midbody was also delayed in cells expressing the 
Plk1 D-box mutant compared with controls expressing wild-
type Plk1 (Fig. 4, C and E). This was matched by a pronounced 
delay in cytokinesis in Plk1 D-box–expressing cells (Fig. 4 C, 
bar graph). No changes in the timing of chromosome segrega-
tion or furrowing were observed (Fig. 4 C, bar graph). These 
findings are consistent with the idea that destruction of Plk1 
provides a mechanism for controlling the recruitment of Cep55 
and thus the timing of abscission.
Premature Cep55 recruitment results  
in aberrant midbody structures
Live cell imaging of EGFP-Cep55 cell lines revealed that fur-
rowing and midbody formation only fail to occur when Plk1 
was inhibited in anaphase A (Fig. 5 A). Once chromosome seg-
regation has occurred, cells treated with BI2536 in anaphase B   
completed furrowing and formed a midbody with timings 
similar to control cells (Fig. 5 B) but remained connected by a 
bridge of cytoplasm and did not complete cytokinesis (Fig. 5 A).   
Importantly, rapid and untimely recruitment of Cep55 to the 
central spindle was observed irrespective of the time of Plk1 
inhibition in anaphase A or B (Fig. 5, A and B). Control cells 
treated with the solvent DMSO alone showed normal timing of 
Cep55 recruitment only once furrowing was completed (Fig. 5, 
A and B). These findings suggest that after Plk1 inhibition or 
upon expression of a Cep55 phosphorylation mutant, cytokinesis 
fails because of misregulation of a late-acting component of the   
abscission machinery. To test this idea, the detailed localization of 
midbody and ESCRT-III components was investigated. When 
Plk1 was inhibited in anaphase using BI2536, midbodies had 
an abnormal architecture (Fig. 5 C). Instead of forming two 
concentric rings on either side of the MKlp1-positive midbody 
structure, Cep55 either formed multilobed structures or a single 
large structure overlapping with MKlp1 (Fig. 5 C). Furthermore, 
although positive for the ESCRT-III component ALIX, these 
midbodies (Fig. S2 B) were functionally abnormal and did not 
recruit the Vps4 AAA-ATPase required for the final step of ab-
scission (Fig. 5 C). These observations support the hypothesis that 
Plk1 is acting as an important regulator of abscission by prevent-
ing Cep55 recruitment to the central spindle earlier in anaphase 
and telophase. Interference with the Plk1 control mechanism 
leads to Cep55 recruitment before midbody formation, which 
perturbs normal midbody architecture and leads to the failure of 
the Vps4-dependent abscission process (Fig. 5 D).
Plk1 is a negative regulator of abscission 
factors in human cells
In this study, we have provided evidence showing that Plk1 is a 
negative  regulator  of  abscission  factors.  By  phosphorylating 
Cep55 at the conserved S436, Plk1 prevents it from interacting 
with the central spindle and midbody protein MKlp1 in ana-
phase cells. Proteomic analysis indicates that Plk1 does not reg-
ulate the interaction of Cep55 with other ESCRT and midbody 
components. Only once the midbody has formed and Plk1 lev-
els are reduced does Cep55 recruitment occur in two concentric 
rings on either side of the midbody core. This timing is critical 
because premature recruitment of Cep55 leads to abnormal mid-
body architecture and abscission failure. Critically, the final 
component of the ESCRT machinery Vps4 does not recognize 
these abnormal midbodies. This suggests a simple mechanism 
for the timing of abscission relative to furrowing and provides a 
reason why the previously described degradation properties of 
Plk1 are important for its function during exit from mitosis 
(Lindon and Pines, 2004). When Plk1 is active at the central 
spindle, it initiates and maintains the cleavage furrow while   
simultaneously preventing abscission factor recruitment. Plk1 
is then degraded by the proteasome and falls to a level unable to 
sustain this inhibition of abscission. Previous work has shown 
that once cells have started anaphase, inhibiting proteasome-
mediated degradation with the drug MG132 causes abscission 
to fail and cells to become binucleate (Straight et al., 2003). 
This is consistent with both the data presented in this study and 
observations that Plk1 degradation is necessary for orderly mi-
totic exit (Lindon and Pines, 2004). A further aspect of the Plk1 
regulation pathway may involve the peptidylprolyl isomerase 
Pin1, although this is unlikely to be cell essential (van der Horst 
and Khanna, 2009; van der Horst et al., 2009). Pin1 is not an es-
sential gene, whereas cytokinesis and abscission are essential 
processes needed for the production of new cells during early 
embryonic development and in the adult. It therefore seems   
unlikely  that  Pin1  regulation  is  critical  for  Cep55  function. 
However, Pin1 may play a role in controlling the level of the Plk1-
phosphorylated form of Cep55 (van der Horst and Khanna, 2009; 
van der Horst et al., 2009). A model in which Pin1 fine tunes 
Cep55 levels before abscission could reconcile these observa-
tions. In the absence of Pin1, excess Cep55 might accumulate and 
interfere with the abscission machinery under some conditions.   757 Plk1 acts as a timer for abscission • Bastos and Barr
are  broadly  in  agreement  with  these  previous  studies  (Fabbro   
et al., 2005; Martinez-Garay et al., 2006; Zhao et al., 2006). How-
ever, in these studies, Plk1 was suggested to be a positive regulator 
of Cep55 function (Fabbro et al., 2005; Zhao et al., 2006). In con-
trast, we show that S436 phosphorylation by Plk1 negatively   
Consistent with this idea, the Cep55 S436A Plk1 phosphorylation-
defective mutant progressively accumulates at the midbody and 
appears to block cytokinesis.
Cep55 has been reported to be an essential regulator of cyto-
kinesis controlled by Cdk1 and Plk1, and the findings in this study 
Figure 4.  Plk1 destruction controls the timing of Cep55 recruitment to the midbody. (A) HeLa cells were mock treated or treated with 100 µM MG132 for 
120 min and stained for DNA with DAPI and mouse anti–-tubulin, rabbit anti-Cep55 or MKlp1 (green), and goat anti-Plk1 (red). Bars, 10 µm. The number 
of Plk1-positive and Cep55-negative midbody structures in the presence and absence of 100 µM MG132 was counted for 120 cells in each of three indepen-
dent experiments. (B and C) HeLa cells stably expressing mCherry-Cep55 and either doxycycline-inducible EGFP-tagged wild-type Plk1 or the D-box mutant 
of Plk1 were imaged every minute with a spinning-disk confocal microscope. At the times indicated (arrows), 100 µM MG132 or 1 µM BI2536 was added. 
Fluorescence intensity of Plk1 and Cep55 was measured for the full central spindle and midbody volume and is plotted against time. A bar graph shows the 
times spent in the different stages of mitosis for 15 cells in three independent experiments. (D and E) Still images of Cep55 behavior in control, MG132, and 
BI2536 (D) cells and wild-type and D-box mutant Plk1 (E) cells are shown. Times are shown in hours:minutes. Error bars indicate SD. Bar, 5 µm.JCB • VOLUME 191 • NUMBER 4 • 2010   758
Figure 5.  Plk1 is required for furrow formation and abscission. (A) HeLa cells expressing mCherry-Cep55 were imaged as they exited mitosis after treat-
ment with either DMSO or 1 µM BI2536. Fluorescence (Cep55) and brightfield (BF) still images from the live cell imaging shown in the bottom panels. 
BI2536 was added as chromosome segregation started in anaphase A or after chromosome segregation, but before furrowing in anaphase B. A dotted 
line marks abscission in the controls samples. Arrows indicate Cep55 recruitment to the central spindle or midbody. Times are shown in hours:minutes from 
the start of anaphase, defined as the time point before chromosome segregation was first detected. (B) The graph shows furrow diameter from the onset 
of anaphase measure in minutes. Arrows show the time of Cep55 recruitment and abscission, if this occurred. (C) HeLa cells treated with DMSO or 1 µM 
BI2536 for 25 min were stained for DNA with DAPI, mouse anti–-tubulin (blue), rabbit anti-Cep55 (green), and sheep anti-MKlp1 (red). (right) HeLa cells 
expressing Vps4-EGFP and Cep55-mCherry were treated with DMSO or BI2536 for 25 min before fixation. Arrows mark the rings of Cep55 and Vps4 
flanking the midbody position. (D) A model summarizing how the timely recruitment of Cep55 may be important for proper ESCRT function at the midbody. 
Bars: (main panels) 5 µm; (enlargements) 1 µm.759 Plk1 acts as a timer for abscission • Bastos and Barr
and nocodazole was removed by washing three times with prewarmed PBS 
and twice with growth medium. At each time point, cells were collected and 
washed three times with ice-cold PBS. Cell pellets were resuspended in lysis 
buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% IGEPAL,   
0.1%  sodium  deoxycholate,  40  mM  -glycerophosphate,  10  mM  NaF,   
0.3 mM Na vanadate, 100 nM okadaic acid, and protease inhibitor cock-
tail [Sigma-Aldrich]), left for 15 min on ice, and clarified by centrifugation 
at 20,000 gav for 20 min at 4°C. Protein complexes were isolated from   
3 mg of cell lysate using 3 µg sheep antibodies against either mCherry, EGFP, 
Cep55, or Mklp1 bound to 20 µl protein G–Sepharose by incubation for   
2 h at 4°C. Isolated complexes were washed three times with lysis buffer 
then twice with 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.1% IGEPAL. 
Samples were analyzed by SDS-PAGE, MS, and Western blotting. Sample 
preparation for MS was performed as described previously (Yoshimura et al.,   
2010). MaxQuant and Mascot (Matrix Science) were used to compile and 
search the raw data against the human International Protein Index data-
base. Protein group and peptide lists were sorted and analyzed in Excel   
(Microsoft) and MaxQuant (Cox and Mann, 2008). MS and MS/MS spec-
tra were inspected using Xcalibur Qualbrowser (Thermo Fisher Scientific).
Live and fixed cell microscopy
Fixed cells on glass slides were imaged using a 60× 1.35 NA oil immer-
sion objective on a standard upright laboratory microscope with a cam-
era (CoolSNAP HQ2; Roper Industries) under the control of MetaMorph 
software (version 7.5; MDS Analytical Technologies). A staging system 
was used to identify the different phases of mitosis and cytokinesis based 
on the DNA and spindle morphology and extent of chromosome alignment 
and separation (Fig. 2 B). For live cell imaging, cells were plated in 2-cm 
dishes with a cover glass window in the bottom. Imaging was performed 
at 37°C in 5% CO2 using an inverted microscope with a 60× 1.42 NA oil   
immersion objective, an electron multiplying charge-coupled device cam-
era (QuantEM 512; Roper Industries), an XY motorized z stage (Piezo; 
Applied Scientific Instrumentation), and a lamp (Lambda DG4; Sutter Instru-
ment Co.) under the control of MetaMorph software or a spinning-disk con-
focal system (Ultraview Vox; PerkinElmer). Image stacks of 25–35 planes 
spaced 0.5–0.7 µm were taken at one to four stage positions every minute 
for 2–12 h. Exposure times were 10–33 ms for EGFP- or mCherry-tagged 
histone H2B, Cep55, Plk1, and tubulin using 1% of full lamp intensity or 
3% laser power. A brightfield reference image stack was collected using 
10-ms exposures. Maximum intensity projection images of the fluorescent 
channels were cropped in ImageJ (National Institutes of Health) and placed 
into Illustrator (CS3; Adobe) to produce the figures. Intensity measurements 
were performed on the full 3D dataset using the volume quantitation and 
object tracking tools of Volocity (version 5; PerkinElmer).
Online supplemental material
Figs. S1–S3 show additional experiments relating to Plk1 regulation of 
Cep55 and the ESCRT protein ALIX. Video 1 shows the timing of Cep55 re-
cruitment to the midbody late during cytokinesis in living cells. Table S1 lists 
the siRNA duplexes used in the study. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201008108/DC1.
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